Technical Sharing Title 4

Beijing time June 12, Burning Rock Biotech listed on NASDAQ. This leader in the tumor gene testing track has received much attention since the news of its listing came out. Investors' enthusiasm was reflected in the secondary market, with the company's stock price opening at $22.8, up 38% from the issue price of $16.5, and then quickly rising, reaching a high of $26.37 during the session, closing up 49.27% at $24.63, with a market value exceeding $2.5 billion. It is reported that Tiger Securities served as the underwriter for Burning Rock Biotech, successfully helping it obtain orders exceeding $360 million, of which the retail side had over 10,000 subscribers, with subscription amounts reaching $223 million, once again breaking Tiger Securities platform's US stock IPO retail subscription record, demonstrating Tiger Securities' unique value as an emerging technology investment bank and strong business synergy capabilities.

"As entrepreneurs, we can better approach and understand Chinese startups, empathize with their pain points in going public, and provide customized services. In addition, our senior US investment banking team, with their in-depth understanding of the US market environment and industry, can provide more targeted professional advice on finance, valuation, and other aspects for these companies. Being a listener and long-term strategic partner for Chinese concept companies, growing together with them, this is what Tiger wants to do." said the head of Tiger Securities' investment banking department. Beijing time June 12, Burning Rock Biotech listed on NASDAQ. This leader in the tumor gene testing track has received much attention since the news of its listing came out. Investors' enthusiasm was reflected in the secondary market, with the company's stock price opening at $22.8, up 38% from the issue price of $16.5, and then quickly rising, reaching a high of $26.37 during the session, closing up 49.27% at $24.63, with a market value exceeding $2.5 billion. It is reported that Tiger Securities served as the underwriter for Burning Rock Biotech, successfully helping it obtain orders exceeding $360 million, of which the retail side had over 10,000 subscribers, with subscription amounts reaching $223 million, once again breaking Tiger Securities platform's US stock IPO retail subscription record, demonstrating Tiger Securities' unique value as an emerging technology investment bank and strong business synergy capabilities. "As entrepreneurs, we can better approach and understand Chinese startups, empathize with their pain points in going public, and provide customized services. In addition, our senior US investment banking team, with their in-depth understanding of the US market environment and industry, can provide more targeted professional advice on finance, valuation, and other aspects for these companies. Being a listener and long-term strategic partner for Chinese concept companies, growing together with them, this is what Tiger wants to do." said the head of Tiger Securities' investment banking department. Beijing time June 12, Burning Rock Biotech listed on NASDAQ. This leader in the tumor gene testing track has received much attention since the news of its listing came out. Investors' enthusiasm was reflected in the secondary market, with the company's stock price opening at $22.8, up 38% from the issue price of $16.5, and then quickly rising, reaching a high of $26.37 during the session, closing up 49.27% at $24.63, with a market value exceeding $2.5 billion. It is reported that Tiger Securities served as the underwriter for Burning Rock Biotech, successfully helping it obtain orders exceeding $360 million, of which the retail side had over 10,000 subscribers, with subscription amounts reaching $223 million, once again breaking Tiger Securities platform's US stock IPO retail subscription record, demonstrating Tiger Securities' unique value as an emerging technology investment bank and strong business synergy capabilities.